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Abstract Sirtuins are a highly conserved family of his-
tone/protein deacetylases whose activity can prolong the
lifespan of model organisms such as yeast, worms and flies.
In mammalian cells, seven sirtuins (SIRT1–7) modulate
distinct metabolic and stress-response pathways, SIRT1
and SIRT3 having been most extensively investigated in
the cardiovascular system. SIRT1 and SIRT3 are mainly
located in the nuclei and mitochondria, respectively. They
participate in biological functions related to development
of heart failure, including regulation of energy production,
oxidative stress, intracellular signaling, angiogenesis,
autophagy and cell death/survival. Emerging evidence
indicates that the two sirtuins play protective roles in
failing hearts. Here, we summarize current knowledge of
sirtuin functions in the heart and discuss its translation into
therapy for heart failure.
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Introduction
Heart failure is a disease with multifactorial causes. Failing
hearts present complex phenotypes, including myocyte
loss, increased fibrosis, diminished response to stresses,
loss of myocardial energetic reserve and reduced myocardial
contractility. Accumulating evidence indicates that epige-
netic modification represents a molecular substrate for cel-
lular stresses, either suppressing or promoting disease
initiation [71]. In particular, lysine residue acetylation is one
of the important posttranslational modifications to regulate
the function of proteins. Sirtuins mediate this posttransla-
tional modification by coupling lysine deacetylation to
NAD? hydrolysis [116]. The dependence of sirtuin activity
on NAD? suggests that their enzymatic activity is directly
linked to the energy and redox status of the cell via the
NAD?/NADH ratio. Among the seven mammalian sirtuins,
SIRT1 and SIRT3 have been most intensively investigated.
Interestingly, SIRT1 and SIRT3 favorably modify cellular
functions that may underlie the above-mentioned heart
failure phenotypes. These sirtuins are crucially involved in
regulation of cardiomyocyte energy metabolism, production
of reactive oxygen species and signaling relevant to cell
death/survival. Biological functions of SIRT1/SIRT3 are
described in this review, mainly from the viewpoint of
translation into therapy for heart failure.
SIRT1 and SIRT3
Mammals express seven sirtuins, SIRT1–7, of which the
molecular weights range from 34 to 62 kDa [78]. All have
an NAD?-dependent catalytic core domain that may act as
an NAD?-dependent deacetylase and/or mono-ADP-ribo-
syl transferase. Additional N-terminal and C-terminal
sequences of variable lengths flank this core domain [78].
SIRT1 is highly expressed in mammalian hearts and reg-
ulates a wide array of cellular processes by deacetylating
histones and a number of non-histone proteins [38]. SIRT1
has been demonstrated to be localized predominantly in the
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nuclei or cytoplasm depending on the cell type. SIRT1
shuttles between the two cellular compartments in response
to cellular stress in C2C12 cells and cardiomyocytes [117,
118] (Fig. 1), and during differentiation in neural precursor
cells [50]. The nucleo-cytoplasmic shuttling is regulated by
nuclear localization signals and nuclear export signals in
the amino acid sequences of SIRT1. PI3K/Akt- and JNK1-
mediated phosphorylation of SIRT1 induces its nuclear
translocation [83, 118]. Nuclear localization of SIRT1
seems to be necessary for its protective function in
cardiomyocytes [117, 118], whereas the biological signif-
icance of cytoplasmic SIRT1 remains to be determined.
SIRT3 has been reported to be a major mitochondrial
deacetylase, although SIRT4 and SIRT5 also reside in the
mitochondria [69]. The full-length human SIRT3 is a
44-kDa protein with an N-terminal mitochondrial locali-
zation sequence [91]. Following import to mitochondria,
142 amino acids from the N-terminus of full-length SIRT3
are cleaved to generate an active 28-kDa short form [91].
Sundaresan et al. [115] reported that the endogenous long-
form SIRT3 was localized in the mitochondria, cytoplasm
and nuclei, whereas the short form of SIRT3 was detected
only in the mitochondria in hearts. Although SIRT3 has
been believed to be a ‘‘mitochondrial sirtuin’’, full-length
SIRT3 in the nucleus is also enzymatically active as indi-
cated by its ability to deacetylate H3 and H4 [101].
As opposed to these findings, a recent study demon-
strated that the endogenous SIRT3 was only evident in
mitochondria and not in the nuclear compartment in H9c2





shuttling of SIRT1 and its
differential distribution. a L929
cells were pre-stained with
Hoechst 33342 and then fused
with COS7 cells transfected
with SIRT1-EGFP
(heterokaryon). SIRT1-EGFP
was detected not only in COS7
nuclei but also in L929 nuclei
(arrows), indicating that SIRT1-
EGFP reached the L929 nucleus






reveals that embryonic (E12.5)
mouse hearts express SIRT1
predominantly in the nuclei,
whereas SIRT1 was diffusely
distributed in the cytoplasm in
adult (3-month-old) mouse
hearts. c The expression levels
of nuclear SIRT1 in the
cardiomyocytes were much
higher in severely failing hearts
from TO-2 hamsters than in
non-failing control hearts.
Produced from ref [118] with
permission
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SIRT3 constructs were detected in sucrose gradient purified
nucleus [12]. These data raise interesting questions as to
whether biological functions of SIRT3 are actually opera-
tional in different subcellular compartment, or whether the
robust overexpression of the protein may evoke artifactual
localization.
Regulation of mitochondrial function and energy
utilization by sirtuins
The role of energy deficits in the development and pro-
gression of heart failure is well established as described
below. In physiological conditions, hearts predominantly
use free fatty acid (FFA) for ATP production (i.e.,
approximately 70 % of total ATP) [4]. In the early stage of
heart failure, the heart switches the substrate to glucose,
which produces more ATP per molecule of oxygen con-
sumed than FFA, at the expense of low energy yield
compared with the yield in FFA oxidation. In advanced
heart failure, however, insulin resistance develops in the
myocardium and glucose utilization declines, limiting ATP
production [128]. Indeed, high-energy phosphate levels
have been shown to be correlated directly with survival in
cardiomyopathy patients [85]. A number of therapies for
heart failure by modulation of myocardial metabolism have
been tested and some of them showed promising results
[8]. Administration of glucagon-like peptide 1 in a canine
pacing-induced cardiomyopathy resulted in increased
GLUT1 expression [17] and significantly improved cardiac
function [86]. Dichloroacetate, an inhibitor of pyruvate
dehydrogenase kinase, augmented glucose and pyruvate
metabolism, leading to improved ejection fraction in
patients with heart failure [16]. Etomoxir inhibits mito-
chondrial carnitine palmitoyltransferase-1 (CPT-1) and
subsequently suppresses long-chain FFA oxidation [70].
The reduction of FFA oxidation by etomoxir was associ-
ated with pyruvate dehydrogenase and phosphofructoki-
nase, leading to enhanced glycolysis and glucose oxidation
[104]. A small pilot study revealed that administration of
etomoxir significantly improved left ventricular ejection
fraction (LVEF) and cardiac output during exercise in
patients with ischemic and dilated cardiomyopathy [103].
Perhexiline, a potent inhibitor of CPT-1 and CPT-2, also
improved LVEF, symptoms of heart failure, MVO2max and
skeletal muscle energetics in a small clinical study [63].
In this context, mitochondrial dysfunction may be one of
the important factors involved in deterioration of ventric-
ular contractile functions, because mitochondria are inte-
grally involved in energy production and metabolism in the
heart [77]. SIRT1 and SIRT3 regulate mitochondrial
functions by deacetylation of nuclear proteins and mito-
chondrial proteins, respectively [73, 78], as described in
detail in the following ‘‘Increased energy production by
SIRT1: indirect modulation of mitochondrial function’’ and
‘‘Evidences arguing against the benefits afforded by SIRT1
in transgenic mice’’. A recent proteomic survey revealed
that most proteins with acetylation residues were localized
in the mitochondria and/or associated with energy metab-
olism [57], arguing for involvement of sirtuins. Functional
properties and expression of mitochondrial proteins is
controlled at both the mitochondrial and nuclear genome
levels. Among approximately 1,500 proteins in the mito-
chondrial proteome, only 13 are expressed by the mito-
chondrial genome; the other mitochondrial proteins are
encoded in the nuclei, synthesized in the cytosol as prep-
roteins that include amino-terminus mitochondrial locali-
zation signal (MLS) and then transported into the
mitochondria [51]. SIRT1 and SIRT3 play diverse roles in
regulation of energy production and oxidative stress as
shown in Fig. 2.
α
Fig. 2 Diverse roles of SIRT1 and SIRT3 in regulation of ATP
production and oxidative stress. SIRT1 shuttles between the nucleus
and cytosol. Nuclear localizing signals and nuclear export signals are
necessary for transport through the nuclear membrane, and the
shuttling is regulated by Akt, JNK-1 and/or NO. In the nucleus,
SIRT1 up-regulates ROS scavengers, Mn-SOD and catalase, and
down-regulates UCP2 and PTP1B. SIRT1 inactivates P53 and
activates PGC-1a by deacetylating the lysine residues. Nuclear-
encoded Mn-SOD translocates into the mitochondria and catabolizes
highly toxic O2
- into less toxic H2O2, which in turn is detoxified to
water. In the mitochondria, SIRT3 deacetylates and activates TCA
cycle enzymes (AceCS2 and IDH2), ETC enzymes (NDUF9 and
NDUFS1) and fatty acid oxidation enzyme (LCAD). SIRT3 also
enhances activity of MnSOD by deacetylation. MOM mitochondrial
outer membrane, MIM mitochondrial inner membrane, IMS inter-
membrane space, PTP1B protein tyrosine phosphatase 1B, UCP2
uncoupling protein 2, AceCS2 acetyl-CoA synthetase 2, LCAD
long-chain acyl co-enzyme A dehydrogenase, IDH2 isocitrate
dehydrogenase 2
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Increased energy production by SIRT1: indirect
modulation of mitochondrial function
SIRT1 suppresses expression of uncoupling protein 2
(UCP2), a mitochondrial inner membrane protein, in
mouse pancreatic cells [20]. Since UCP2 functions to
uncouple oxygen consumption from ATP production [53],
suppression of UCP2 expression by SIRT1 results in
increased mitochondrial ATP production [18, 31]. In
addition, SIRT1 induces a substrate shift for energy pro-
duction. SIRT1 interacts with and deacecylates PPAR
gamma coactivator-1a (PGC-1a), a master switch of
mitochondrial biogenesis, and induces gluconeogenic
genes, resulting in increased glucose output in mouse liver
and skeletal muscle [64, 97]. PPAR gamma coactivator-1a
also regulates fuel utilization in muscle cells by increasing
fatty acid oxidation and shutting down glucose oxidation
[35]. The level of PGC-1a protein in failing human hearts
was lower by approximately 30 % than that in non-failing
control hearts [34], and decreased PGC-1a mRNA levels
were associated with impairment of mitochondrial bio-
genesis and function in rodent models of heart failure [7,
126]. These findings indicate that insufficient activity of
PGC-1a may lead to mitochondrial dysfunction and heart
failure. Collectively, activation of PGC-1a by SIRT1 and
enhanced mitogenesis may restore energy metabolism in
the failing myocardium and ameliorate heart failure. Con-
sistent with this notion, resveratrol, a SIRT1 activator,
preserved mitochondrial mass and biogenesis and sup-
pressed cardiac dysfunction in Dahl salt-sensitive rat fed
with a high-salt diet, a model of hypertensive heart failure
[96].
The improved insulin sensitivity by SIRT1 is also a
potential mechanism by which SIRT1 preserves contractile
function in failing hearts. It has been demonstrated that
resveratrol, an SIRT1 activator, improves insulin sensitiv-
ity in diet-induced obesity in mice [13, 60]. Sun et al. [113]
found that SIRT1 repressed protein phosphatase 1B
(PTP1B) and thereby increased the level of insulin receptor
phosphorylation, improving insulin sensitivity both in
C2C12 myotubes and in high fat-fed mice. Resveratrol
ameliorated pathological histology, such as vacuolization,
degeneration and inflammation, in the hearts of high fat-fed
mice with impaired insulin sensitivity [13]. PPAR gamma
coactivator-1a has been shown to be decreased in aging
murine hearts [121], which may be due, at least in part, to
decreased SIRT1 expression [98]. The decrease in PGC-1a
protein in hearts may be responsible for the predisposition
of aging hearts to heart failure. Interestingly, a recent study
demonstrated that SIRT1 and PGC-1a are localized in
mitochondria and form a multiprotein complex with
mitochondrial transcription factor A in mouse liver and
HeLa cells [5], suggesting their involvement in
mitochondrial biogenesis not only by regulation of nuclear-
encoded proteins, but also by direct control of mitochon-
drial gene expression.
Evidences arguing against the benefits afforded
by SIRT1 in transgenic mice
In contrast to generally favorable effects of pharmacolog-
ical activation of SIRT1 on the heart, results from SIRT1-
overexpressing animals have been somewhat contradictory.
Alcendor et al. [2] demonstrated that moderate overex-
pression of Sirt1 up to 7.5-fold attenuated age-dependent
cardiac dysfunction and oxidative stress-induced apoptosis
in mouse hearts, whereas a higher level (12.5-fold) of
overexpression of Sirt1 increased apoptosis and hypertro-
phy and decreased cardiac function. Similarly, Kawashima
et al. [54] demonstrated that constitutive cardiac-specific
overexpression of SIRT1 at a high level (20-fold) caused
dilated cardiomyopathy and that moderate (6.8-fold)
overexpression of SIRT1 impaired cardiac diastolic func-
tion. Furthermore, fatty acid uptake was decreased,
degenerated mitochondria increased and the expression of
genes relevant to mitochondrial function decreased, in
proportion to SIRT1 gene dosage. Transgenic mice with an
even lower level of SIRT1 overexpression (3.2-fold)
developed cardiac dysfunction upon pressure overload,
although their basal cardiac function was preserved. Oka
et al. [88] also provided evidence that overexpression of
SIRT1 may deteriorate mitochondrial function and exac-
erbate cardiac dysfunction by suppressing expression of
genes regulated by estrogen-related receptors in
cardiomyocytes.
The reason for the discrepancy concerning the effects on
ventricular functions between pharmacological activation
and overexpression of SIRT1 is unclear, but there are some
plausible explanations. First, gene dosage may have been
too high even with low-level overexpression. Although a
larger amount of SIRT1 is expected to produce a higher
level of deacetylase activity, too much SIRT1 protein may
cancel the protective effect through non-specific deacety-
lation and/or deacetylase-independent detrimental effects,
e.g., interaction with other proteins and un-physiological
subcellular distribution. Second, consequences of consti-
tutive activation of SIRT1 may be different from those of
temporary or intermittent activation. In agreement with this
notion, transient transfection of SIRT1 deacetylated PGC-
1a and increased fatty acid oxidation in a skeletal myocyte
cell line [35], whereas stable transfection with SIRT1
impaired cellular respiration in PC12 cells [84]. Third,
beneficial effects afforded by SIRT1 might not be appli-
cable to myocardial damage induced by certain stressors.
Kawashima et al. [54] and Oka et al. [88] employed severe
pressure overload by transverse aortic constriction to
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induce heart failure. They demonstrated that overexpres-
sion of SIRT1 further promoted cardiac dysfunction,
whereas Alcendor showed that moderate overexpression of
SIRT1 rendered hearts resistant to oxidative stress-induced
damage by paraquat.
Increased energy production by SIRT3: direct
modulation of ATP-producing machinery
SIRT3 appears to play a role in cellular energy production at
multiple steps, i.e., up-regulation of fatty acid oxidation,
supply of intermediates for the TCA cycle and activation of
the electron transport chain (ETC). SIRT3 interacts with
acetyl-CoA synthetase 2 (AceCS2), a cardiac-enriched
mitochondrial enzyme that promotes entry of acetate into the
tricarboxylic acid cycle in the form of acetyl-CoA, in Cos-7
cells. Sirt3 deacetylates lysine 642 of AceCS2 and activates
its enzymatic activity [42]. SIRT3 also targets long-chain
acyl co-enzyme A dehydrogenase (LCAD). Mass spec-
trometry of mitochondrial proteins in liver extracts from
SIRT3-/- mice has shown that LCAD is hyperacetylated at
lysine 42. Hyperacetylation of LCAD reduces its enzymatic
activity, suggesting that deacetylation of LCAD-K42 by
SIRT3 increases fatty acid oxidation output [49]. Further-
more, exogenously transfected myc-tagged SIRT3 physi-
cally interacts with NDUF9, a subunit of complex I in the
mitochondrial ETC, and deacetylates and activates the
enzyme, thus augmenting ATP production in SIRT3-/-
mouse embryonic fibroblasts (MEFs) [1]. A recent study
demonstrated that activities of ETC complexes I, III and IV,
were decreased by approximately 30, 70 and 60 %, respec-
tively, in livers of Sirt3-/- mice fed a high-fat diet compared
with the activities in wild-type animals on the same diet [55].
Most of the above-mentioned findings were demon-
strated in the liver tissue. However, it is likely that SIRT3
is also a major regulator of ATP synthesis in cardiac
mitochondria, as indicated by the following evidences.
First, prolonged caloric restriction, an intervention known
to activate SIRT1/SIRT3 and extend lifespan in several
species, including rhesus monkeys [30, 122], decreased the
amount of acetylated forms of NDUFS1 in complex I and
Rieske subunit of cytochrome bc1 in complex III in
cardiomyocytes [107]. Second, mice lacking SIRT3, which
exhibit a striking hyperacetylation of mitochondrial pro-
teins [69], showed 50 % lower basal levels of ATP in the
heart [1].
Unexpectedly, the SIRT3-/- mice showed normal sys-
tolic function despite the substantial reduction of ATP
[114]. This apparent contradiction may be explained by at
least a few possibilities. First, diastolic function may be
more susceptible to the decline in the level of myocardial
ATP than systolic function. Indeed, there was a significant
correlation between the ATP level and pulmonary capillary
wedge pressure, but not ejection fractions in human hearts
[111]. Second, ATP levels measured in whole heart may
reflect neither ATP levels in close proximity to cytosolic
ATPases, including myosin ATPase and SERCA, nor rate
of ATP utilization by these enzymes. In this regard, the
level of phosphocreatine and creatinine kinase activity,
molecules that regulate energy transport and utilization,
may be more closely associated with the contractile func-
tion than the level of ATP [59, 85]. In contrast, Hirschey
et al. [49] demonstrated that ATP levels in the liver were
normal at baseline in SIRT3-/- mice, though 24-h fasting
resulted in significantly lower hepatic ATP levels in
SIRT3-/- mice than in wild-type mice. These findings
indicate that the cellular energy production/utilization is
maintained by redundant mechanisms. They may partly
compensate for each other when one is ablated, but the
compensation may fail when the energy demand increases
under stress conditions.
Regulation of ROS by sirtuins
Reactive oxygen species (ROS) damage macromolecules
within and outside the mitochondria. The mitochondrial
ETC is the main source of ROS in most cells [11]. Hearts
consume large amounts of O2 and yield high levels of ROS
in the mitochondria. In addition, various extracellular
factors, such as angiotensin II and tumor necrosis factor-a,
induce ROS formation and promote cardiomyocyte death
together with the mitochondrial ROS [36]. Among the
many anti-oxidant defense systems, mitochondrial man-
ganese superoxide dismutase (Mn-SOD) plays a pivotal
role in the detoxification of ROS. Mice deficient in Mn-
SOD have an enlarged heart with endocardial fibrosis and
die within the first 10 days of life [66]. Furthermore, long-
term reduction of Mn-SOD activity by heterozygous
deletion of the Mn-SOD gene impairs left ventricular
functions: MnSOD?/- mice displayed a decrease in ejec-
tion fraction and developed cardiac hypertrophy with
fibrosis and necrosis [68]. In the clinical arena, patients
with hemochromatosis, in which iron overload induces
robust oxidative stress, have a significantly higher preva-
lence of cardiomyopathy if MnSOD activity is reduced by
a mutation in the Mn-SOD gene [123].
Both SIRT1 and SIRT3 reportedly up-regulate Mn-SOD
expression, though the mechanisms are different for the
two sirtuin (i.e., HIF-2a [32] and/or FOXO4 [124] versus
FOXO3a [114]). Nuclear localization was required for
SIRT1 to up-regulate Mn-SOD [117], and this might also
be the case with SIRT3. Sundaresan et al. [115] demon-
strated that overexpression of nuclear SIRT3 that lacks the
MLS protected cardiomyocytes from genotoxic stress and
oxidant stress as did overexpression of wild-type
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mitochondrial SIRT3. Manganese superoxide dismutase is
unlikely to be the only ROS scavenger under regulation by
SIRT1. Alcendor et al. [2] recently reported that heart-
specific overexpression of SIRT1 inhibited oxidative
stress-induced damage by paraquat and that this cardio-
protection seemed to be achieved by up-regulation of the
protein level of catalase via transcriptional activation of
FOXO1a.
It is notable that SIRT3 increases ROS scavenging
activity of Mn-SOD by deacetylating K53/K68 [95] and
K122 [119] in MEFs, in addition to its effect on protein
level of Mn-SOD [114]. SIRT3 also increases activity of
other ROS-detoxifying enzymes indirectly. SIRT3 deace-
tylates and activates the TCA cycle enzyme isocitrate
dehydrogenase 2 (IDH2) and glutamate dehydrogenase in
murine liver [69, 102], both of which produce NADPH in
the mitochondria. NADPH in turn is required for gluta-
thione reductase to convert oxidized glutathione to
reduced glutathione, which is a crucial cofactor for
mitochondrial glutathione peroxidase to scavenge ROS.
Consistent with these findings, Shinmura et al. [107]
demonstrated that treatment of cardiomyocytes with res-
veratrol, an activator of SIRT1 and SIRT3, decreased ROS
production and improved cell survival after hypoxia/
reoxygenation without increasing the expression level of
MnSOD protein.
Recently, mitochondrial aldehyde dehydrogenase 2
(ALDH2) has been identified as a novel target of SIRT3
[72]. Excessive ROS in stressed hearts triggers lipid per-
oxidation and accumulation of reactive aldehydes, which in
turn impairs mitochondrial function and induces cell
damage. Aldehyde dehydrogenase 2 reduces the toxicity by
removal of the aldehydes, resulting in cardioprotection
[23]. Taken together, SIRT3-mediated ALDH2 activation
could be another mechanism that mitigates cardiomyocyte
damage induced by ROS. However, the protective mech-
anism may not operate in non-cardiac tissues, as acetami-
nophen hepatotoxicity was rather exacerbated by ALDH2
in mice [72].
Regulation of angiogenesis by sirtuins
Cardiac hypertrophy occurs as an adaptive response to
increased workload to maintain cardiac function. However,
under a prolonged stress condition, this program becomes
maladaptive, resulting in myocyte death, fibrosis, ventric-
ular dilation and eventually transition to heart failure. It has
been shown that both heart size and cardiac function are
angiogenesis dependent, and disruption of coordinated
cardiac muscle growth and angiogenesis in the heart con-
tributes to the progression from adaptive cardiac hyper-
trophy to heart failure [99, 108].
Several lines of evidence indicate that SIRT1 plays
crucial roles in compensatory angiogenesis. Potente et al.
[94] demonstrated that SIRT1 was highly expressed in the
vasculature during blood vessel growth. Knockdown of
SIRT1 by siRNA in human umbilical vein endothelial cells
(HUVECs) blocked sprouting angiogenesis with down-
regulation of genes involved in blood vessel development.
Endothelial cell-specific deletion of SIRT1 in mice blunted
ischemia-induced neovascularization in the hindlimb [94].
Conversely, activation of SIRT1 by resveratrol induced
up-regulation of vascular endothelial growth factor
(VEGF) and its tyrosine kinase receptor Flk-1, along with
nitric oxide synthase (inducible NOS and endothelial NOS)
3 weeks after myocardial infarction, resulting in increased
capillary density in rats [33]. Induction of angiogenesis by
SIRT1 seemed to be mediated by inhibition of Foxo1, an
essential negative regulator of blood vessel development,
because SIRT1 interacts and deacetylates Foxo1 in
HUVECs [94].
In addition to direct up-regulation of angiogenic factors,
inactivation of p53, an anti-angiogenetic factor, might be a
mechanism by which SIRT1 regulates angiogenesis. Sano
et al. [99] demonstrated that sustained pressure overload on
the left ventricle induces up-regulation of p53. P53 in turn
inhibits activity of hypoxia-inducible factor-1 (HIF-1), a
transcription factor that regulates the expression of genes
involved in hypoxic adaptation including VEGF [47].
Indeed, the inactivation of HIF-1 was causally related to
down-regulation of angiogenic factors, reduction in capil-
lary density and transition from adaptive hypertrophy to
heart failure [99]. SIRT1 deacetylates and reduces tran-
scriptional activity of p53 in cardiomyocytes [3], and HIF-
1 increases the expression level of SIRT1 protein [24].
Thus, fine-tuned balance between activities of SIRT1 and
p53 may determine the extent of angiogenesis in the
pressure-overloaded heart and transition from compensated
hypertrophy to decompensated heart failure. So far,
involvement of SIRT3 in angiogenesis has not been
reported.
Modulation of cardiomyocyte Ca21 handling by sirtuins
During excitation–contraction coupling, Ca2? entry
through L-type Ca2? channels triggers Ca2? release from
the sarcoplasmic reticulum (SR) through ryanodine recep-
tors, raising free intracellular Ca2? concentration from the
nanomolar range in the diastole to the micromolar range in
the systole. The increase of the concentration allows Ca2?
to associate with troponin C, a myofilament protein,
resulting in sarcomere shortening and muscle contraction.
Subsequent muscle relaxation is initiated by Ca2? disso-
ciation from the troponin complex, when Ca2? is removed
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from the cytoplasm by Ca2? handling machinery. In
humans, SERCA2a is responsible for 70 % of the removal
by taking up Ca2? into the SR, and the rest is extruded by
the Na2?/Ca2? exchanger (28 %) and plasma-membrane
Ca2? ATPase (2 %) [40]. Earlier studies demonstrated that
intracellular Ca2? handling was abnormal in the failing
human myocardium, and this abnormality appears to be
one of the mechanisms responsible for systolic and dia-
stolic dysfunction [39]. Particularly, impaired Ca2? uptake
into the SR through SERCA2a has been demonstrated to be
associated with heart failure; SERCA2a mRNA was
decreased in patients with dilated or ischemic cardiomy-
opathy [6] and aging rat hearts [75], and down-regulation
of SERCA2A protein and/or impaired SERCA2a function
was observed in animal model of diabetic cardiomyopathy
[15, 26] and human dilated cardiomyopathy [67].
Knowledge of the role of sirtuins in intracellular Ca2?
regulation in cardiomyocyte is limited. However, a study
has shown that reduced SERCA2a protein level, ventricular
dysfunction, ventricular dilatation and mortality in a mouse
model of type-1 diabetes were nearly normalized by
treatment with resveratrol [112]. They also demonstrated
that in cultured cardiomyocytes, SERCA2a promoter
activity that was highly repressed by high-glucose media
was significantly improved by resveratrol in an SIRT1-
dependent manner [112]. In light of the universal nature of
down-regulation of SERCA2a protein/mRNA and its dys-
function in heart failure, whether activation of SIRT1
ameliorates heart failure irrespective of the etiology war-
rants investigation.
Regulation of cell death/survival by sirtuins
Loss of cardiomyocytes and their replacement with reac-
tive fibrosis are important causative factors in the devel-
opment of heart failure. Cardiomyocyte death in failing
hearts is induced by multiple mechanisms: apoptosis,
necrosis, and autophagic cell death [58]. SIRT1 and SIRT3
have been demonstrated to modify these types of cell death
via diverse mechanisms as described below.
Modulation of apoptotic machinery
Ku70 has been recognized as a subunit of the Ku protein
complex, which plays an important role in DNA damage
repair. Ku70 is associated with Bax, a pro-apoptotic Bcl-2
family protein, in its deacetylated form. However, acety-
lation of Ku70 induced by cellular stress facilitates the
release of Bax from Ku70 and induces its mitochondrial
translocation, resulting in apoptosis [28, 100]. Caloric
restriction up-regulates SIRT1 and maintains residues
K539 and K542 of Ku70 in a deacetylated form, keeping
Bax sequestered away from mitochondria, thereby inhib-
iting stress-induced apoptosis in 293 cells [29]. Recently,
Nagalingam et al. showed that SIRT3 is catalytically active
outside the mitochondria and also targets Ku70. They
demonstrated that deacetylation of Ku70 by SIRT3 pro-
motes Ku70/Bax interaction in Hela cells, and this makes
cells resistant to Bax-mediated cell damage [115], as was
the case with SIRT1-induced Ku70 deacetylation. Full-
length SIRT3-expressing cells were resistant to cell death
induced by MNNG (N-methyl-N0-nitro-N-nitrosoguani-
dine) even when SIRT1 was knocked out, indicating that
SIRT1 and SIRT3 have redundant functions to protect cells
from apoptosis [115].
p53 is the first non-histone substrate found to be
deacetylated by SIRT1 [74]. Acetylation of p53 is required
for recruitment of transcription co-factors of PUMA and
Bax, proapoptotic genes, to their promoter regions and
activation of the promoter [21]. SIRT1 deacetylates p53
and silences the pro-apoptotic activity of p53 [110].
SIRT1-deficiency was associated with hyperacetylation of
p53 and increased sensitivity to apoptosis induced by
ionizing radiation in thymocytes [25]. Inhibition of SIRT1
by nicotinamide (NAM), an SIRT1 inhibitor, elevated the
acetylation level and activity of p53, resulting in cardio-
myocyte death. Conversely, expression of dominant nega-
tive p53 prevented NAM-induced cardiomyocyte death [3].
In failing hearts, the increased activity of poly(ADP-ribose)
polymerase-1, which induces NAD? depletion, was asso-
ciated with reduced SIRT1 activity and increased acetyla-
tion of p53 at K373/K382 [90]. Collectively, these findings
support the notion that p53 deacetylation by SIRT1 is
crucial for cardiomyocyte survival.
It has also been reported that SIRT1 suppressed apop-
tosis via mechanisms that were independent of the deace-
tylase activity. The protective effect of SIRT1 in neurons
against low potassium-induced apoptosis was observed
even after pharmacological inhibition of SIRT1 by nico-
tinamide and sirtinol, or transfection of mutant SIRT1 that
lacks deacetylase activity [89]. These observations indicate
that non-catalytic mechanisms may also play a role in
SIRT1-mediated cell survival under certain stresses in
some types of cells.
SIRT3 was also found to interact with p53. SIRT3
directly deacetylates p53, thereby abrogating its activity to
execute growth arrest and senescence in bladder carcinoma
cells [65]. However, the role of SIRT3 in regulation of p53-
mediated apoptosis in cardiomyocytes has not yet been
clarified.
Suppression of mPTP opening
The mitochondrial permeability transition pore (mPTP) is a
large conductance channel in the mitochondrial inner
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membrane that non-selectively passes molecules\1.5 kDa
in response to its opening stimuli. Mitochondrial perme-
ability transition pore opening has been shown to be
involved in cell necrosis by a variety of causes including
ischemia/reperfusion and anti-cancer agents [48, 129].
While acute robust irreversible opening of the mPTP can
lead to cell necrosis, chronic low-level opening of the
mPTP induces swelling and membrane depolarization of
mitochondria and removal of defective mitochondria by
autophagy [56]. Indeed, mitochondria of young animals are
relatively small and bioenergetically efficient, but with
aging they become swollen and less numerous, and
chronically depolarized [127], leading to decreased mito-
chondrial function, decreased tolerance to stress and
increased susceptibility to cell death [19].
Accumulating evidence indicates that sirtuins are
involved in the regulation of stimuli for mPTP opening and
the mPTP itself. The levels of intracellular ATP and ROS
and intramitochondrial Ca2? are major determinants of the
threshold of mPTP opening, and these factors are critically
regulated by SIRT1 and/or SIRT3 as discussed above.
Contribution of p53 to mPTP-mediated necrosis is indi-
cated by the findings that an inhibitor of p53, pifithrin-a,
sensitized the myocardium to cardioprotection afforded by
isoflurane and that this beneficial effect of pifithrin-a was
abolished by atractyloside, an activator of mPTP [125].
The impact of sirtuin-mediated regulation of p53 on mPTP
opening remains to be determined.
As for direct modulation of the mPTP by sirtuins, inter-
action of SIRT3 with cyclophilin D (CyPD) has been
recently reported. Cyclophilin D is one of the cyclophilin
family proteins with peptidylprolyl isomerase (PPIase)
activity and localizes primarily in the mitochondrial matrix
under baseline conditions. In response to cellular stress such
as ischemia/reperfusion, CyPD interacts with inorganic
phosphate carrier and adenine nucleotide translocase on the
mitochondrial inner membrane in cardiomyocytes, leading
to sensitization of the mPTP to opening stimuli [79]. In fact,
genetic ablation of CyPD or treatment with cyclosporine A,
an inhibitor of CyPD, elevates the threshold for opening of
the mPTP and affords tolerance against ischemia/reperfu-
sion-induced necrosis [9, 10, 27, 81, 93]. Shulga et al. [109]
showed that SIRT3 deacetylates CyPD and inhibits its PPI-
ase activity in HeLa cells. Furthermore, Hafner et al. [41]
confirmed that CyPD was deacetylated at Lys166 by SIRT3
in cardiac tissue. They also demonstrated that an increase in
Ca2? sensitivity of the mPTP by aging was significantly
enhanced in cardiac mitochondria isolated from SIRT3-
knockout mice. These findings indicate that SIRT3 coun-
teracts increased sensitivity of the mPTP in response to
cellular stress in failing and aging hearts.
Regulation of cell-protective signaling
Sensing intracellular energy balance, AMP-activated pro-
tein kinase (AMPK) is activated to reserve cellular energy
content. Activated AMPK can promote the metabolic
pathways relevant to ATP production such as cellular
glucose uptake and fatty acid oxidation, while it switches
off ATP-consuming anabolic pathways. AMP-activated
protein kinase also serves as a key regulator of cell survival
in response to pathological stress, such as ischemia/reper-
fusion, endoplasmic reticulum stress and hypoxia [46, 87,
120]. SIRT1 and SIRT3 activate serine–threonine liver
kinase B1 (LKB1), one of the many upstream kinases of
AMPK, in human embryonic kidney 293 cells [61] and in
cardiomyocytes [92], respectively. Furthermore, the inter-
play between sirtuins and AMPK might be reciprocal,
because AMPK enhances activity of SIRT1 by enhancing
the intracellular NAD?/NADH ratio in C2C12 myocytes
[22]. Cardioprotective effects afforded by exogenous
NAD? were mediated by SIRT3-induced LKB1 activation
and subsequent AMPK phosphorylation [92]. There are
many downstream targets of AMPK [14], among which
inhibitory phosphorylation of GSK3b [92, 105] and
up-regulation of GLUT4 protein [87] appear to play a role
in cardioprotection.
Nuclear localization of SIRT1 was necessary for
up-regulation of Mn-SOD protein and cell protection against
necrosis under oxidant stress in C2C12 myoblast cells
[117]. In this context, signals that facilitate nuclear import
of SIRT1 should be important for SIRT1 to protect cells
from death. Nuclear localization of SIRT1 in cardiomyo-
cytes was inhibited by use of the PI3K/Akt inhibitor
LY294002, suggesting a role of Akt-mediated phosphory-
lation in the nuclear translocation of SIRT1 [118]. Simi-
larly, human SIRT1 was phosphorylated by JNK1 on
Ser27, Ser47 and Thr530 under oxidative stress, and this
phosphorylation of SIRT1 increased its nuclear localization
and enzymatic activity. Interestingly, JNK1-induced
phosphorylation of SIRT1 showed substrate specificity
resulting in deacetylation of histone H3 but not that of p53
[83]. Six-month calorie restriction in rats significantly
increased the protein level of SIRT1 in the nucleus,
deacetylation of histone H3 and myocardial tolerance
against ischemia/reperfusion injury. Treatment with
N-nitro-L-arginine methyl ester, an inhibitor of nitric oxide
(NO) synthase, prevented the increase in nuclear Sirt1 and
cardioprotection in calorie-restricted animals [106]. These
findings indicate a role of NO in nuclear translocation of
SIRT1 (Fig. 2), but relationships of NO with Akt and JNK
in the regulation of intracellular localization of SIRT1
remain to be determined.
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Regulation of autophagy by sirtuins
Autophagy is a dynamic process of intracellular bulk deg-
radation in which cytosolic proteins and organelles are
sequestered into double-membrane vesicles called auto-
phagosomes to be fused with lysosomes for degradation. In
nutrient-deprived cells, autophagy serves as a cell survival
mechanism by degrading intracellular proteins and lipids to
recycle them for generation of ATP [76, 80]. Under stressed
conditions, autophagy selectively removes damaged mito-
chondria [56]. Since damaged mitochondria release
pro-apoptotic factors such as cytochrome c, autophagy can
prevent activation of apoptotic machinery [44]. In cardiac
tissues, autophagy has been demonstrated to play a protective
role [37]. Enhancing autophagy by beclin1 overexpression
reduces Bax activation and protects cardiac HL-1 cells
against ischemia/reperfusion injury [43]. Tamoxifen-
induced temporal and cardiac-specific knockout of Atg5, a
protein involved in autophagosome formation, led to left
ventricular dilatation and contractile dysfunction with
misalignment and aggregation of mitochondria in mice
[82]. Akt overexpression in mice suppressed autophagy,
which was associated with cardiac hypertrophy, interstitial
fibrosis and contractile dysfunction [52].
SIRT1 regulates autophagy by interacting with and deace-
tylating autophagy-related proteins Atg5, Atg7 and Atg8
[62]. Recently, Hariharan et al. [45] demonstrated that
SIRT1 was required for starvation-induced autophagy in
cardiomyocytes, in which SIRT1-mediated deacetylation
of FOXO1 and subsequent activation of Rab7 play a role.
Furthermore, FOXO1 was indispensable for maintenance
of cardiac function after starvation. Thus, it is plausible that
autophagy induced by activation of the SIRT1-FOXO1 axis
is an important adaptive mechanism in the failing heart,
which is potentially starved of energy.
Conclusion
Sirtuins are a unique class of proteins that link acetylation
status of proteins to a wide variety of physiological func-
tions and diseases. Our understanding of the biology of
SIRT1 and SIRT3 has expanded considerably over the past
decade, with numerous novel targets being identified. The
bulk of emerging evidence indicates that these sirtuins are
involved in numerous biological functions including reg-
ulation of energy production, detoxification of oxidative
stress, promotion of angiogenesis, intracellular Ca2? han-
dling, suppression of cell death and induction of autoph-
agy. Since derangement of these physiological processes
underlies the development/progression of heart failure,
pharmacologic activation of SIRT1 and/or SIRT3 poten-
tially ameliorates the disease. In agreement with this
notion, oral administration of resveratrol preserved cardiac
function and improved survival in various animal models
of heart failure (Fig. 3). Although more work is needed to
fully understand the role of sirtuins in cardiac cell biology,
a sirtuin-activating compound could be one of the prom-
ising future therapeutic approaches for heart failure.
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